• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Quest Diagnostics (NY: DGX )

    147.35 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 147.35
    Bid (Size) 147.32 (1)
    Ask (Size) 234.28 (1)
    Prev. Close 147.35
    Today's Range 147.35 - 147.35
    52wk Range 119.59 - 150.59
    Shares Outstanding 122,180,759
    Dividend Yield 1.93%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
    The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
    Via Benzinga

    Performance

    YTD
    +4.64%
    +4.64%
    1 Month
    +5.08%
    +5.08%
    3 Month
    +13.27%
    +13.27%
    6 Month
    +12.73%
    +12.73%
    1 Year
    +2.31%
    +2.31%

    More News

    Read More
    How Is The Market Feeling About Quest Diagnostics?
    Via Benzinga
    Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
    From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
    Via GlobeNewswire
    EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
    Via Benzinga
    S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Peering Into Quest Diagnostics's Recent Short Interest
    Via Benzinga
    Analyst Scoreboard: 7 Ratings For Quest Diagnostics
    Via Benzinga
    How Is The Market Feeling About Quest Diagnostics?
    Via Benzinga
    Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
    Via MarketBeat
    Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
    Via AB Newswire
    Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
    Via Talk Markets
    Peering Into Quest Diagnostics's Recent Short Interest
    Via Benzinga
    The Analyst Landscape: 5 Takes On Quest Diagnostics
    Via Benzinga
    Balancing Dividends and Fundamentals: The Case of NYSE:DGX.
    Via Chartmill
    Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
    Via Benzinga
    DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory'
    Via Benzinga
    Why NYSE:DGX provides a good dividend, while having solid fundamentals.
    Via Chartmill
    Earnings Scheduled For April 23, 2024
    Via Benzinga
    Key Takeaways From Quest Diagnostics Analyst Ratings
    Via Benzinga
    Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
    Via Benzinga
    LifeMD Shares Come Back to Life on GLP-1 Business Growth
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.